Stock Track | Tandem Diabetes Care Soars 11.53% Intraday on Better-Than-Expected Q1 Results and Improved Outlook

Stock Track05-08

Tandem Diabetes Care's stock surged 11.53% intraday, driven by the company's strong first-quarter financial performance that exceeded analyst expectations.

The medical device maker reported Q1 sales of $247.2 million, a 5% year-over-year increase, while its net loss narrowed to $20.4 million from $130.6 million a year earlier. The company's adjusted loss per share of $0.30 beat the consensus estimate of $0.45, and revenue surpassed expectations of $241.13 million. Gross margin improved significantly to 55%, up 4.8 percentage points from the prior year, reflecting operational efficiency gains.

Business developments including record pump shipments exceeding 29,000 units worldwide, the launch of a pay-as-you-go reimbursement model in the U.S. pharmacy channel, and the expansion of its connected care ecosystem contributed to the positive results. The company also reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion and projected gross margin of 56%-57%. Analyst sentiment remained positive with TD Cowen maintaining a Buy rating and $28 price target, citing strengthening fundamentals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117500924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 15:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117500924","market":"sg","top_or_hot":-1,"title":"Stock Track | Tandem Diabetes Care Soars 11.53% Intraday on Better-Than-Expected Q1 Results and Improved Outlook","media":"Stock Track","content":"<p>Tandem Diabetes Care's stock surged 11.53% intraday, driven by the company's strong first-quarter financial performance that exceeded analyst expectations.</p><p>The medical device maker reported Q1 sales of $247.2 million, a 5% year-over-year increase, while its net loss narrowed to $20.4 million from $130.6 million a year earlier. The company's adjusted loss per share of $0.30 beat the consensus estimate of $0.45, and revenue surpassed expectations of $241.13 million. Gross margin improved significantly to 55%, up 4.8 percentage points from the prior year, reflecting operational efficiency gains.</p><p>Business developments including record pump shipments exceeding 29,000 units worldwide, the launch of a pay-as-you-go reimbursement model in the U.S. pharmacy channel, and the expansion of its connected care ecosystem contributed to the positive results. The company also reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion and projected gross margin of 56%-57%. Analyst sentiment remained positive with TD Cowen maintaining a Buy rating and $28 price target, citing strengthening fundamentals.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tandem Diabetes Care Soars 11.53% Intraday on Better-Than-Expected Q1 Results and Improved Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tandem Diabetes Care Soars 11.53% Intraday on Better-Than-Expected Q1 Results and Improved Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 15:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tandem Diabetes Care's stock surged 11.53% intraday, driven by the company's strong first-quarter financial performance that exceeded analyst expectations.</p><p>The medical device maker reported Q1 sales of $247.2 million, a 5% year-over-year increase, while its net loss narrowed to $20.4 million from $130.6 million a year earlier. The company's adjusted loss per share of $0.30 beat the consensus estimate of $0.45, and revenue surpassed expectations of $241.13 million. Gross margin improved significantly to 55%, up 4.8 percentage points from the prior year, reflecting operational efficiency gains.</p><p>Business developments including record pump shipments exceeding 29,000 units worldwide, the launch of a pay-as-you-go reimbursement model in the U.S. pharmacy channel, and the expansion of its connected care ecosystem contributed to the positive results. The company also reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion and projected gross margin of 56%-57%. Analyst sentiment remained positive with TD Cowen maintaining a Buy rating and $28 price target, citing strengthening fundamentals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"Tandem Diabetes","start_time":0,"source_url":"","article_id":"1117500924","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117500924","pubTimestamp":1778224531,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tandem Diabetes Care's stock surged 11.53% intraday, driven by the company's strong first-quarter financial performance that exceeded analyst expectations.The medical device maker reported Q1 sales...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"Tandem Diabetes"},"translate_title":"个股追踪|Tandem Diabetes Care盘中大涨11.53%，Q1业绩好于预期，前景改善","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"Tandem Diabetes Care's stock surged 11.53% intraday, driven by the company's strong first-quarter financial performance that exceeded analyst expectations.The medical device maker reported Q1 sales of $247.2 million, a 5% year-over-year increase, while its net loss narrowed to $20.4 million from $130.6 million a year earlier. The company's adjusted loss per share of $0.30 beat the consensus estimate of $0.45, and revenue surpassed expectations of $241.13 million. Gross margin improved significantly to 55%, up 4.8 percentage points from the prior year, reflecting operational efficiency gains.Business developments including record pump shipments exceeding 29,000 units worldwide, the launch of a pay-as-you-go reimbursement model in the U.S. pharmacy channel, and the expansion of its connected care ecosystem contributed to the positive results. The company also reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion and projected gross margin of 56%-57%. Analyst sentiment remained positive with TD Cowen maintaining a Buy rating and $28 price target, citing strengthening fundamentals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117500924","isCrawlerRequest":true}